Blood pressure development in adolescents diagnosed with gender dysphoria assigned male at birth treated with gonadotropin-releasing hormone analogues and gender affirming hormones


Adolescents diagnosed with gender dysphoria (GD) are treated with gonadotropin-releasing hormones analogues (GnRHa) from age 11 and subsequently gender affirming hormones (GAH) are added from the age of 16. Overall, this... [ view full abstract ]


This study aimed to determine the effect of endocrine treatment on blood pressure in adolescent natal boys diagnosed with GD. [ view full abstract ]

Main Outcome Measures

Adolescent natal boys diagnosed with GD (transgirls) at VU University Medical Center who were eligible for treatment were included for participation after signing the informed consent form. Exclusion criteria were:... [ view full abstract ]


SDS of 24-h, diurnal and nocturnal SBP and DBP (corrected for height and natal sex or height and desired sex) during GnRHa monotherapy or during GAH therapy. [ view full abstract ]


In 38 transgirls (median age 13.3 years [3.3]) ABPM was measured prior to start of GnRHa and during a median duration of GnRHa monotherapy of 11.5 months [4.0]. SDS (corrected for height and natal sex) of 24-h SBP and 24-h DBP... [ view full abstract ]


BP did not change during GnRHa monotherapy in transgirls. Since androgens are known to have a BP elevating effect (Reckelhoff, Hypertension, 2001), the gonadal suppression would have been expected to lower BP. This discrepancy... [ view full abstract ]


Nienke Bosman (VU Medical Center, Department of Endocrinology and Center of Expertise on Gender Dysphoria, Amsterdam), Daniel Klink-Scholten (VU Medical Center, Department of Endocrinology and Center of Expertise on Gender Dysphoria, Amsterdam)

Topic Area

Oral & Poster Topics: Endocrinology


OS-2C » Endocrinology II (11:00 - Friday, 7th April, Atlantic 3)

Presentation Files

The presenter has not uploaded any presentation files.